Skip to main content
TipRanks
Go Ultimate75% OFF

First Tracks Biotherapeutics Inc (TRAX) AI Stock Analysis

57 Followers
TRAX

First Tracks Biotherapeutics Inc

(NASDAQ:TRAX)

Select Model
Rating:49Neutral
Price Target:$52.00▲(16.96% Upside)
Action:reiterated
Date:10/29/26

The score is held down primarily by weak financial performance (no revenue, large and worsening losses, and significant cash burn), which raises ongoing funding risk. Technical momentum is a meaningful offset (price above key moving averages with a positive MACD), but valuation support is limited due to negative earnings and no dividend yield data.

Positive Factors
Clinical validationPositive Phase 1b efficacy and tolerability data provide clinical validation for ANB033 and support progression toward later-stage development. If confirmed in subsequent studies, this evidence could strengthen the company’s product prospects and improve its ability to address an unmet need in celiac disease.
Negative Factors
No commercial revenueThe absence of revenue means the company currently lacks a commercial funding engine and remains dependent on capital markets or other financing sources. Negative gross profit and ongoing development spending also indicate that commercial self-sufficiency is not yet established.

First Tracks Biotherapeutics Inc (TRAX) vs. SPDR S&P 500 ETF (SPY)

-50%0%50%100%150%200%TRAX+134.00%SPY+8.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.87B
Dividend Yield
―
Average Volume (3M)
827.07K
Price to Earnings (P/E)
-9.9
Beta (1Y)
0.48
Revenue Growth
―
EPS Growth
―
Country
US
Employees
104
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

First Tracks Biotherapeutics Inc Business Overview & Revenue Model

Company Description

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflamm...

First Tracks Biotherapeutics Inc Financial Statement Overview

Summary

Financial fundamentals are weak: no revenue reported across 2023–2025, persistent and worsening net losses (-$166.1M in 2025 vs. -$163.7M in 2024 and -$106.2M in 2023), and heavy operating cash burn (-$142.9M in 2025). The main positive is low leverage (debt-to-equity ~0.04–0.05), but the declining equity base increases future financing/dilution risk.

Income Statement

14Very Negative

Balance Sheet

63Positive

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023
Income Statement
Total Revenue0000
Gross Profit-1.20M-139.61M-152.34M0
EBITDA-119.27M-176.58M-178.70M-116.08M
Net Income-115.21M-166.09M-163.71M-106.15M
Balance Sheet
Total Assets170.46M330.55M441.89M444.11M
Cash, Cash Equivalents and Short-Term Investments155.63M311.64M385.37M390.90M
Total Debt3.77M14.11M16.04M17.81M
Total Liabilities19.45M43.05M50.30M34.26M
Stockholders Equity151.01M287.49M391.60M409.85M
Cash Flow
Free Cash Flow-81.57M-143.01M-126.16M-93.81M
Operating Cash Flow-81.53M-142.93M-125.81M-93.00M
Investing Cash Flow34.96M228.03M95.40M144.75M
Financing Cash Flow-36.00M30.01M117.52M-87.09M

First Tracks Biotherapeutics Inc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TRAX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
XNCRXNCR61Neutral$2.55B-21.66-21.29%―33.55%11.51%
REPLREPL55Neutral$1.82B-6.89-157.78%――19.12%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TRAXTRAX49Neutral$1.87B-9.90-72.93%―――
KURAKURA48Neutral$675.31M-2.23-336.24%―-23.76%-33.09%
CTMXCTMX46Neutral$446.91M-4.54-33.97%―-87.66%-210.45%
ALLOALLO40Underperform$231.06M-1.06-49.84%――36.37%

* Healthcare Sector Average

Performance Comparison

0%100%TRAXXNCRCTMXKURAREPLALLODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TRAX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TRAXFirst Tracks Biotherapeutics Inc44.4625.46134.00%
XNCRXencor Inc.34.0117.27103.17%
CTMXCytomX Therapeutics Inc.2.05-1.92-48.36%
KURAKura Oncology7.35-4.38-37.34%
REPLReplimune Group19.239.84104.79%
ALLOAllogene Therapeutics0.67-0.68-50.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026